Rozlytrek and Dizziness - a phase IV clinical study of FDA data

Summary:

Dizziness is reported as a side effect among people who take Rozlytrek (entrectinib), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Eliquis, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Dizziness when taking Rozlytrek. It is created by eHealthMe based on reports of 735 people who have side effects when taking Rozlytrek from the FDA, and is updated regularly.

What is Rozlytrek?

Rozlytrek has active ingredients of entrectinib. eHealthMe is studying from 736 Rozlytrek users. Check the latest studies of Rozlytrek.

What is Dizziness?

Dizziness is found to be associated with 3,566 drugs and 5,710 conditions by eHealthMe. Check the latest studies of Dizziness.

On Jul, 13, 2026

735 people reported to have side effects when taking Rozlytrek.
Among them, 80 people (10.88%) have Dizziness.

Among these 80 people:

How long have people been on Rozlytrek when they have Dizziness? *

What is the gender of people who have Dizziness when taking Rozlytrek? *

female: 60 %
male: 40 %

What is the age of people who have Dizziness when taking Rozlytrek? *

What are other drugs people take besides Rozlytrek? *

What are other side effects people have besides Dizziness? *

Constipation: 14 people, 17.50%
Fatigue (feeling of tiredness): 10 people, 12.50%
Weakness: 10 people, 12.50%
Fall: 8 people, 10.00%
Hypotension (abnormally low blood pressure): 8 people, 10.00%
Ageusia (loss of taste functions of the tongue): 7 people, 8.75%
Nausea (feeling of having an urge to vomit): 7 people, 8.75%
Diarrhea: 7 people, 8.75%
Weight Increased: 6 people, 7.50%
Rashes (redness): 6 people, 7.50%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 34 people, 42.50%
Lung Cancer - Non-Small Cell (lung cancer): 21 people, 26.25%
Thyroid Cancer: 3 people, 3.75%
High Blood Pressure: 3 people, 3.75%
Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 3.75%
Neoplasm Malignant (cancer tumour): 2 people, 2.50%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 2 people, 2.50%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 2 people, 2.50%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 2.50%
Sarcoma (rare cancers that develop in the muscle, bone, nerves, cartilage, tendons, blood vessels and the fatty and fibrous tissues): 2 people, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Rozlytrek and have Dizziness?

- Check whether Dizziness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rozlytrek:

Rozlytrek (736 reports)

Dizziness treatments and more:

Dizziness (613,960 reports)

Browse all side effects of Rozlytrek:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dizziness:

Dizziness (3,566 drugs)

Browse all the conditions that are associated with Dizziness:

Dizziness (5,710 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on entrectinib (the active ingredients of Rozlytrek) and Rozlytrek (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.